Intensive Treatment of glucose levels in diabetes patients

Intensive treatment of glucose levels in diabetes patients can lead to serious complications

Getty Images/iStockphoto/ThinkStock

Intensive attempts to lower glucose levels in diabetes patients can lead to serious harm for patients, particularly for older patients with other medical conditions, according to a new study from the Mayo Clinic. They findings from the study were published online on June 6 in JAMA Internal Medicine.

For the purposes of this study, “intensive treatment” was defined as being treated with more glucose-lowering medications than clinical guidelines consider necessary given a patient’s HbA1C level. Patients whose HbA1C was less than 5.6 were considered intensively treated if they were taking any medications. Patients with HbA1C in the prediabetes range, 5.7-6.4%, were considered to be intensively treated if using two or more medications at the time of the test, or if started on additional medications after the test, because current guidelines consider patients with HbA1C less than 6.5% to be optimally controlled already. For patients with HbA1C of 6.5-6.9%, the sole criteria for intensive treatment was treatment intensification with two or more drugs or insulin.

Read also: New study aims to identify genetic factors in diabetic kidney disease 

“At first, we were surprised to find how much overtesting for HbA1C is occurring among adults of all ages with Type 2 diabetes who were already well-controlled,” said Rozalina McCoy, MD, a Mayo Clinic primary care physician and endocrinologist, and lead author of the study. “But, then, we realized that not only were patients being tested frequently, they were also being treated with more medications than we would expect considering how low their HbA1C already was. So, this led us to do this study— to see how frequently patients are treated so intensively that they may be overtreated and what that does to their risk of hypoglycemia.”

The researchers examined medical claims, pharmacy and laboratory data of 31,542 adults with stable and controlled Type 2 diabetes who were included in the OptumLabs Data Warehouse between 2001 and 2013. None of the patients were treated with insulin or had prior episodes of severe hypoglycemia —both known risk factors for future hypoglycemic events. None of the patients had obvious indications for tight glycemic control, such as pregnancy.

“Our goal was to specifically assess the degree to which intensive treatment— not other known risk factors, such as prior hypoglycemic events or insulin therapy —caused hypoglycemia,” said McCoy. “We also wondered if young and healthy patients may be better able to tolerate intensive treatment than older patients or those with complex medical problems, so we specifically looked at the impact of intensive treatment on these two groups separately.”

The patients were separated by whether they were considered clinically complex, as defined by the American Geriatrics Society: 75 years or older; having end-stage kidney disease or dementia; or having three or more serious chronic conditions. This distinction has been made to help identify patients for whom adding glucose-lowering medications is more likely to lead to treatment-related adverse events, including hypoglycemia, while not providing substantial long-term benefit.

Of the 31,542 p

Home Dialyzors United

Our Day, Our Way

Sign up and receive our latest updates!

With this information HDU can keep you informed of news and issues, including one quarterly Newsletter.

You may, of course, choose to opt out at any time by contacting HDU at

Click Here to go directly to the website.

It has been Nichole Jefferson‘s personal mission to tell her story and promote awareness. She was diagnosed with end-stage renal disease (ESRD) in October 2003. At that time, not only was she unaware of what that meant; she also did not know she was a high-risk factor for developing the disease.
After the initial shock of the diagnosis, she decided peritoneal dialysis (PD) was the best option and utilized PD for a few years until she needed to switch to hemodialysis.
She received a kidney transplant from a deceased donor on June 12, 2008, but at the time, she didn’t realize it was simply another form of treatment and not a cure. Today, Nichole is waiting for a new transplant.
Nichole has worked with many advocacy groups on Capitol Hill and has provided her personal experience with ESRD to leaders in the field of nephrology. She tries to express the feelings of those who are unable or unwilling to speak for themselves.